In what was considered an unusual move toward clinical transparency, Medtronic gave Yale researchers its trial data on the bone growth treatment Infuse, and the researchers found that the product was no more effective than a bone graft. Results were published in the journal Annals of Internal Medicine. "The move that we made to open up everything out there and hold them up to transparent treatment was the right thing to do," said Christopher J. O'Connell, president of Medtronic's restorative therapies group. Roche and GlaxoSmithKline have agreed to release some trial data as well.

Related Summaries